The median PFS in the PD1 + RT group had significant longer than TACE + sorafenib group across sub­groups based on age ≥ 53, infection of hepatitis B (HBV), the maximum tumor diameter < 10 cm, MVI, without extrahepatic metastasis, BCLC stage C, no prior TACE, prior hepatectomy, and no prior systemic therapy (P = 0.01, 0.04, 0.031, 0.024, 0.049, 0.0067, 0.044, 0.024 and 0.016; respectively, Fig. 4A). Here, PDCD1 is linked to neoplasm.